Gout in a rheumatology clinic: results of EULAR/ACR guidelines-compliant treatment

Area of Science:

• Rheumatology
• Clinical Medicine

Background:

• Gout treatment in primary care often falls short of recommended serum urate targets (<0.36 mmol/l), with less than 25% of patients achieving success.
• There is a need for evaluating specialized treatment protocols for effective gout management.

Purpose of the Study:

• To assess the effectiveness of specialized European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) guidelines-based treatment for gout in a rheumatology clinic setting.
• To measure treatment outcomes, specifically the achievement of target serum urate levels and disease control.

Main Methods:

• A prospective observational study analyzed data from 100 new, crystal-proven gout patients.
• Treatment involved a treat-to-target (T2T) approach with urate-lowering therapy (ULT) and flare prophylaxis (colchicine) in 93 and 90 patients, respectively.
• Patient demographics included 88 males (mean age 62.1 years) and 12 females (mean age 74.1 years), with a mean disease duration of 8.6 years.

Main Results:

• The treat-to-target (T2T) approach was successfully reached in 85% of patients within an average of 4.7 months.
• A well-controlled disease state, defined by sustained T2T achievement and absence of flares, was achieved by 82% of patients after approximately 10.4 months.
• Reasons for not reaching T2T included low compliance (10 patients) and adverse effects or nephropathy (5 patients).

Conclusions:

• Adherence to EULAR/ACR guidelines, incorporating verified diagnosis, patient education, T2T with ULT, and flare prophylaxis in a rheumatology clinic, yields high success rates.
• This specialized treatment strategy effectively achieved therapeutic goals in 85% of gout patients.
• The study highlights the importance of a structured, guideline-based approach for optimizing gout management.